GMP Protein (E. coli) Contract Manufacturing Market to Surpass US$ 1,439.1 Mn by 2030

Global GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, and Others}, IVT Enzymes, and Others] Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex-Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 685.8 Million in 2022 and is expected to exhibit a CAGR of 9.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

The increasing adoption of inorganic growth strategies such as acquisitions by the key players in the market is expected to drive market growth over the forecast period. For instance, in January, Thermo Fisher Scientific Inc., a global biotechnology company, announced that it had acquired PeproTech, Inc., a developer and manufacturer of recombinant proteins including cytokines and growth factors. This acquistions will help Thermo Fisher Scientific Inc.,to expand its recombinant proteins product portfolio.

Global GMP Protein (E. coli) Contract Manufacturing Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector that has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries has placed an economic burden on the private healthcare sector. Healthcare providers were facing challenges with manpower, equipment, consumables, and other resources to ensure safety in the treatment of patients with other diseases, declining outpatients’ visits, etc. Moreover, the coronavirus pandemic has negatively impacted the development, production, and supply of drugs as well as the growth of healthcare businesses across the globe. This has led to the closure of industrial establishments, except the manufacture of essential commodities, and disruption in the supply chain of products. The pandemic has affected the economy in three main ways; 1) by directly affecting production and demand; 2) by creating disruptions in distribution channels, and 3) through its financial impact on companies and financial markets. Supply chain and manufacturing activities in India, China, the U.S., and others have been disrupted due to lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and others are facing problems with the transportation of drugs and medications. Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global GMP protein (E. coli) contract manufacturing market to a certain extent during the forecast period

Global GMP Protein (E. coli) Contract Manufacturing Market: Key Developments

In April, Thermo Fisher Scientific, a global biotechnology company, launched their new Gibco CTA TrueCut Cas9 protein, which was produced under GMP standards to support genome editing for both research and industrial applications.

In January, Bio-Techne Corporation, a developer and manufacturer of purified proteins and reagent solutions, announced the plans to invest US$ 40-50 million to increase its GMP-grade protein production capacity. This investment will fund a new facility that is specifically dedicated to supporting the large-scale production of GMP grade materials, including E. coli-derived recombinant proteins.

Browse 71 Market Data Tables and 65 Figures spread through 603 Pages and in-depth TOC on “Global GMP Protein (E. coli) Contract Manufacturing Market”- Forecast to 2030, Global GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, Others}, IVT Enzymes, and Others], Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex- Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/gmp-protein-e-coli-contract-manufacturing-market-5433

Moreover, increasing product launches by the key players is expected to drive market growth over the forecast period. For instance, in August 2022, Canvax Reagents S.L., a manufacturer & supplier of solutions, services, kits, and research and development reagents for the molecular & cell biology field, announced the launch of an improved Inorganic Pyrophosphatase (PPAse), a DNA replication enhancer with high purity (≥ 95%) and enhanced capacity of increasing RNA yield in In Vitro Transcription (IVT) reactions. Canvax Pyrophosphatase is stable under temperatures below 80°C

Key Takeaways of the Global GMP Protein (E. coli) Contract Manufacturing Market:

• The global GMP protein (E. coli) contract manufacturing market is expected to exhibit a CAGR of 9.7% during the forecast period due to the increasing prevalence of chronic diseases such as as cancer, neutropenia anemia, hepatitis, Crohn’s disease, as gmp protein are used in the treatment of chronic diseases. For instance, according to the data provided by the World Health Organization in February 2022, the most common types of cancer were breast cancer accounting for 2.26 million cases, and lung cancer accounting for 2.21 million cases in the year 2020, globally.
• Among end user, the biotechnology and pharmaceutical companies segment is estimated to hold a dominant position in the global GMP protein (E. coli) contract manufacturing market over the forecast period, owing to the increasing acquisitions between biotechnology and pharmaceutical companies. For instance, in March 2022, FUJIFILM Irvine Scientific, Inc., a firm that develops and manufactures serum-free and chemically defined cell culture media for a variety of applications such as life science research, announced the acquisition of Shenandoah Biotechnology, Inc., a leading developer of recombinant proteins. This acquisition will provide customers worldwide with a single point of contact for cGMP cell culture solutions for biopharmaceuticals, cell and gene therapies, and other applications.
• On the basis of region, North America is estimated to account for the largest market share in the global GMP protein (E. coli) contract manufacturing market over the forecast period, owing to increasing clinical trials and research and development activities by research institutes in the region. For instance, in March 2021, Genome Institute (IGI), a research partnership between the University of California, Berkeley, and the University of California, San Francisco, announced that it is conducting a new trial using CRISPR-Cas9 nuclease to stimulate repair of the sickle mutation by replacing the normal DNA segment for the abnormal one. The CRISPR-Cas9 nuclease is a fully assembled Cas9 protein and guides RNA sequence targeting the defective region of the beta-globin gene. The final manufacturing protocol has been verified in pre-clinical safety/toxicology studies carried out following consultation with the U.S. FDA. CRISPR-Cas9 nuclease uses a virus-free technique to alter blood stem cells.
• Major players operating in the global GMP protein (E. coli) contract manufacturing market include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.